TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2018; 39(09): 581-585DOI: 10.1055/a-0664-2530 Schwerpunkt Hepatozelluläres Karzinom © Georg Thieme Verlag KG Stuttgart · New York Steatohepatitis und Steatohepatitis-getriebener Leberkrebs Mathias Heikenwälder Recommend Article Abstract Buy Article Kalorienüberschuss und sitzende Lebensweise mit wenig Bewegung haben zu einer globalen Epidemie von Fettleibigkeit geführt. Es gibt zunehmend epidemiologische Hinweise darauf, dass die hepatische Konsequenz – die nicht alkoholische Fettlebererkrankung (NAFLD) – in vielen Fällen für die Entstehung des hepatozellulären Karzinoms (HCC) verantwortlich ist. Wir fassen den aktuellen Stand der Forschung auf diesem Gebiet zusammen. Full Text References Literatur 1 Swinburn BA. et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814 2 Adams LA. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153 3 Younossi Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20 4 Bhaskaran K. et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755-765 5 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 6 Burt AD. et al. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 2015; 35: 207-220 7 Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline. Hepatology 2012; 55: 2005-2023 8 Younossi ZM. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84 9 Buzzetti E. et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048 10 Anstee QM. et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 11 Krenkel O. et al. Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis. Hepatology 2018; 67: 1270-1283 12 Boyle M. et al. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol 2018; 68: 251-267 13 Hart CL. et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Brit Med J 2010; 340: C1240 10.1136/Bmj.C1240 14 Singh S. et al. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol 2015; 13: 643-654 15 Jemal A. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 16 Ascha MS. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978 17 Sanyal A. et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191 18 Piscaglia F. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838 19 Ohnishi S. et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev 2013; 2013: 387014 . doi:10.1155/2013/387014 20 Lin R. et al. Chronic inflammation-related DNA damage response: a driving force of gastric cardia carcinogenesis. Oncotarget 2015; 6: 2856-2864 21 Boege Y. et al. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell 2017; 32: 342-359 22 Campisi J. et al. Cellular senescence: when bad things happen to good cells. Nature Rev Molec Cell Biol 2009; 8: 729-740 23 Fumagalli M. et al. SASPense and DDRama in cancer and ageing. Nat Cell Biol 2009; 11: 921-923 24 Nishida N. et al. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 1646-1653 25 Tanaka S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol 2013; 48: 1249-1258 26 Pascale RM. et al. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?. DNA Repair 2016; 47: 12-20 27 Kubes P. et al. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172 28 Davis BK. et al. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735 29 Arrese M. et al. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci 2016; 61: 1294-1303 30 Lanthier N. Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?. World J Hepatol 2015; 7: 2184-2188 31 Bieghs V. et al. The innate immune response during liver inflammation and metabolic disease. Trends Immunol 2013; 34: 446-452 32 Shalapour S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551: 340-345 33 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 34 Heimbach JK. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380 35 Dyson J. et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117 36 Taylor EJ. et al. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017; 66: 1546-1555 37 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140 38 Bruix J. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017; 67: 999-1008 39 Mehnert JM. et al. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 2017; 23: 4970-4979 40 Ogle LF. et al. Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. J Hepatol 2016; 65: 305-313 41 Mishra SI. et al. Exercise interventions on health-related quality of life for cancer survivors. The Cochrane database of systematic reviews. 2012: CD007566 42 Mishra SI. et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. The Cochrane database of systematic reviews. 2012: CD008465 43 Gustafson MP. et al. A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. J Immunother Cancer 2017; 5: 30 44 Idorn M. et al. Exercise: A new role for an old tool. Mol Cell Oncol 2016; 3: e1163005 45 Koelwyn GJ. et al. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 2017; 17: 620-632
